Niemann-Pick's and Gaucher's diseases

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Stern, Gerald ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Clinical and molecular features; Enzyme replacement therapy; Glucocerebrosidase mutations and Parkinson's disease; Lysosomal storage disease; Niemann Pick's and Gaucher's diseases

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE;

ARTICLE; AUTOPHAGY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; GENETIC VARIABILITY; GLUCOCEREBROSIDASE GENE; HUMAN; MITOPHAGY; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN AGGREGATION; RISK FACTOR; SUBSTANTIA NIGRA; TREATMENT PLANNING;

CLINICAL AND MOLECULAR FEATURES; ENZYME REPLACEMENT THERAPY; GLUCOCEREBROSIDASE MUTATIONS AND PARKINSON'S DISEASE; LYSOSOMAL STORAGE DISEASE; NIEMANN-PICK'S AND GAUCHER'S DISEASES;

GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HISTORY, 20TH CENTURY; HUMANS; MUTATION; NIEMANN-PICK DISEASES;

EID: 84887882549     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70034-8     Document Type: Article

References (26)

1. Hers HG α-Glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963, 86:11-16.
2. Gaucher PCE. De l'epithélioma primitif de la rate. Hypertrophie idiopathique de la rate sans leucémie. Thèse de médecine de Paris no. 31; 1882.
3. Niemann A Ein unbekanntes Krankheitsbild. Jahrbuch für Kinderheilkd Neue Folge (Berlin) 1914, 79:1-10.
4. Pick L Über die lipoidzellige Splenohepatomegalie Typus Niemann-Pick als Stoffwechselerkrankung. Med Klin 1927, 39:1483.
5. Suzuki K, Suzuki K Lysosomal diseases. Greenfield's Neuropathology 2008, 515-599. Hodder Arnold. 8th Edition.
6. Enzyme Replacement Therapy - Type B. Research news April 2012, National Niemann-Pick Disease Foundation.
7. Grabowski GA Lysosomal storage disease 1, Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008, 372:1263-1271.
8. Brady RO The sphingolipidoses. N Engl J Med 1966, 275:59-70.
9. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324:1464-1470.
10. Shayman JA, Abe A, Hiraoka M A turn in the road: how studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity. Glycoconj J 2004, 20:25-32.
11. Patores GM, Barnett NL, Kolodny EH An open-label non-comparative study of miglustat in type 1 Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005, 27:1215-1227.
12. Van Bogaert L, Froelich A Un cas de maladie de Gaucher de l'adulte avec syndrome de Raynaud, pigmentation et rigidité du type extrapyramidal aux members inférieurs. Ann Med (Paris) 1939, 45:57-70.
13. Davison D Disturbances in lipoid metabolism and the central nervous system. J Mt Sinai Hosp 1942, 9:389-406.
14. Neil JF, Glew RH, Peters SP Familial psychosis and diverse neurologic abnormalities in adult-onset Gaucher's disease. Arch Neurol 1979, 36:95-99.
15. McKeran RO, Bradbury P, Stern G Neurological involvement of type 1 (adult) Gaucher's disease. J Neurol Neurosurg Psychiatry 1985, 48:172-175.
16. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. Occurrence of Parkinson's syndrome in type 1 Gaucher's disease. Q J Med 1996, 89:691-694.
17. Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003, 61:99-101.
18. Pastores GM, Barnett NL, Bathan P, Kolodny EH A neurological symptom survey of patients with type 1 Gaucher's disease. J Inherit Metab Dis 2003, 26:641-645.
19. Goker-Alpan O, Schiffman R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E Parkinsonism among Gaucher disease carriers. J Med Genet 2004, 41:937-940.
20. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher's disease. Mol Genet Metab 2004, 82:192-207.
21. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson's disease brains. Ann Neurol 2012, 72:455-463.
22. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Gluco-cerbrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006, 67:908-910.
23. Sidransky E Gaucher's disease and parkinsonism. Mol Genet Metab 2005, 84:302-304.
24. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009, 132:1783-1794.
25. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. N Engl J Med 2009, 361:1651-1661.
26. Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.